160893-07-2

Usage

Uses

Used in Pharmaceutical Synthesis:
2-Chloro-5-Methoxyquinoline is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic properties.
Used in Antimicrobial Applications:
In the field of microbiology, 2-Chloro-5-Methoxyquinoline is utilized as an antimicrobial agent, leveraging its capacity to inhibit the growth of various microorganisms, thereby offering a potential solution for combating microbial infections.
Used in Antifungal Applications:
2-Chloro-5-Methoxyquinoline also serves as an antifungal agent, effective against a range of fungi, making it a candidate for applications in treating fungal infections and controlling fungal growth in various settings.
Used in Research on Inflammation and Oxidative Stress:
Due to its ability to modulate pathways involved in inflammation and oxidative stress, 2-Chloro-5-Methoxyquinoline is used as a research tool in biomedical studies to better understand these processes and to develop treatments for related conditions.
Used in Organic Chemistry:
In the realm of organic chemistry, 2-Chloro-5-Methoxyquinoline is employed as a building block for the synthesis of other organic compounds, contributing to the advancement of chemical research and the creation of novel materials.

Upstream product

• 186581-53-3 diazomethane 
• 124467-35-2 2-chloro-5-hydroxyquinoline 
• 90924-16-6 5--methoxyquinoline N--oxide 
• 578-67-6 quinolin-5-ol 
• 6931-19-7 5-methoxyquinoline 
• 160893-04-9 5-methoxy-2(1H)-quinolinone 
• 611-34-7 5-Aminoquinoline 
• 607-34-1 5-nitroquinoline 

Relevant academic research and scientific papers

Design and synthesis of new 2-anilinoquinolines bearing N-methylpicolinamide moiety as potential antiproliferative agents

A series of new 2-anilinoquinolines 6a–o possessing the substantial N-methylpicolinamide motif at C5 has been designed and synthesized as sorafenib analogs. The antiproliferative activities of the target compounds were preliminarily appraised against a panel of three human cancer cell lines (MCF-7, SK-BR3, and HCT116), and a selected array was further tested over a panel of approximately 60 cancer cell lines at NCI at 10?μM concentration. Interestingly, compounds 6c, 6d, 6j, 6k, and 6l showed promising selective anticancer activities (growth inhibition >80%) toward certain cancer cells at 10?μM testing dose. Compounds 6d and 6j were advanced to five-dose testing mode to determine their GI50 values and compared with our previously reported ureidoquinoline B and sorafenib as reference compounds. The 4-chloro-3-trifluoromethylaniline derivative 6j manifested superior potency than both compound B and sorafenib over eleven and eight cell lines, respectively. It showed GI50 values of 0.36, 0.66, 0.68, and 0.60?μM against the breast MDA-MB-468, renal A498, and melanoma SK-MEL-5 and UACC-62 cell lines, respectively. Moreover, both 6d and 6j exerted low cytotoxic effects against HFF-1 normal cell line. Furthermore, compounds 6d and 6j were tested against both B-RafV600E and C-Raf kinases and displayed modest inhibitory activities, which were justified by molecular docking study. Compound 6j could serve as a promising candidate for further development of potent anticancer chemotherapeutics.

2-Anilinoquinoline based arylamides as broad spectrum anticancer agents with B-RAFV600E/C-RAF kinase inhibitory effects: Design, synthesis, in vitro cell-based and oncogenic kinase assessments

Prompted by the urgent demand for identification of new anticancer agents with improved potency and efficacy, a new series of arylamides incorporating the privileged 2-anilinoquinoline scaffold has been designed, synthesized, and biologically assessed. Ai

NOVEL QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCER CONTAINING THE SAME

The present invention refers to an excellent cancer antiproliferative potency relative to the quinoline compounds, a pharmaceutically acceptable salt, or hydrate and, number of active ingredient containing bath method and pharmaceutical composition for the prevention or treatment of cancer disease relates to search, said present invention according to compound, a pharmaceutically acceptable salt thereof, or hydrate number and number and mutant kinase protein kinase activity number of excellent cancer billion billion number activity and thus, new anticancer number is useful as the effective component can be. (by machine translation)

Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening

A series of new 2-anilinoquinolines possessing 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety at C5 of quinoline has been designed and synthesized as potential anticancer agents. Their antiproliferative activities were evaluated against a panel of 60 cancer cell lines at NCI and compared with gefitinib as a reference compound. Most of the tested compounds displayed potent and broad spectrum antiproliferative activities. Compounds 7d, 7f and 7g showed strong inhibitory and lethal effects at 10?μM concentration. Moreover, they manifested superior potencies and efficacies than gefitinib across the most tested cell lines. Compound 7d, with 4-chloro-3-trifluoromethylphenyl group, proved to be the most potent and efficacious derivative in this series, with mean GI50and TGI values of 1.62?μM and 3.47?μM, respectively. Kinase screening of 7d against a panel of 47 oncogenic kinases revealed its selective inhibitory effect (96% inhibition) towards TrkA kinase. Furthermore, the most potent compounds showed low cytotoxic effects against HFF-1 normal cell line.

Design, synthesis, in-vitro antiproliferative activity and kinase profile of new picolinamide based 2-amido and ureido quinoline derivatives

Abstract New 2-amido and ureido quinoline derivatives substituted with 2-N-methylamido-pyridin-4-yloxy group at the 5-position of quinoline (18 final compounds) have been designed and synthesized as anticancer sorafenib congeners. Among the synthesized de

2-(Substituted ethynyl)quinoline Derivatives as mGLUr5 Antagonists

Provided is a 2-(substituted ethynyl)quinoline derivative having an mGluR5 antagonistic activity and pharmaceutically acceptable salts thereof. The compound of the present invention can be useful as a medicament for treating and preventing mGluR5 receptor

Synthesis and in vivo evaluation of 5-methoxy-2-(phenylethynyl)quinoline (MPEQ) and [11C]MPEQ targeting metabotropic glutamate receptor 5 (mGluR5)

The synthesis and in vivo evaluation of 5-methoxy-2-(phenylethynyl) quinoline (MPEQ) 3 as a potential mGluR5 selective radioligand is described. We have identified MPEQ 3 exhibiting the analgesic effect in the neuropathic pain animal model. The effect of mGluR5 on neuronal activity in rat brain was evaluated through FDG/PET imaging in the presence of MPEQ 3. In addition, the PET study of [11C]MPEQ 3 proved that accumulation of [ 11C]MPEQ 3 in rat brain was correlated to the localization of the mGluR5.

Synthesis and biological evaluation of 2-(arylethynyl)quinoline derivatives as mGluR5 antagonists for the treatment of neuropathic pain

We described here the synthesis and biological evaluation of mGluR5 antagonists containing a quinoline ring structure. Using intracellular calcium mobilization assay (FDSS assay), we identified compound 5n, showing high inhibitory activity against mGluR5. In addition, it was found that compound 5n has excellent stability profile. Finally, this compound exhibited favorable analgesic effects in spinal nerve ligation model of neuropathic pain, which is comparable to gabapentin.

II. Synthesis and biological evaluation of some bioisosteres and congeners of the antitumor agent, 2-{4-[(7-chloro-2-quinoxalinyl)oxylphenoxy}propionic acid (XK469)

XK469 (1) is among the most highly and broadly active antitumor agents to have been evaluated in our laboratories. Subsequent developmental studies led to the entry of (R)-(+) 1 (NSC 698215) into phase 1 clinical trials (NIH UO1-CA62487). The antitumor me

SYNTHESIS OF 5-METHOXY-2(1H)-QUINOLINONE

Methylation of 5-hydroxy-2(1H)quinolinone (1) is studied.The previous protection of the amide group in 1 is proposed as the more convenient method to obtain 5-methoxy-2(1H)-quinolinone (1a).